Sino Biopharm Secures $2.1B TQC3721 AstraZeneca Agreement
HONG KONG, July 8, 2026 Sino Biopharmaceutical Limited has announced that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co.,...
AstraZeneca
Advertisement
CSPC Pharma Secures Up to $1.77B AstraZeneca siRNA Deal
HONG KONG, July 2, 2026 CSPC Pharmaceutical Group Limited has announced a strategic collaboration, option and license agreement with...
Abbisko and AstraZeneca Advance Oral PD-L1 Therapy for NSCLC
SHANGHAI, China, July 1, 2026 Abbisko Therapeutics and AstraZeneca have entered into a strategic collaboration to advance the clinical...
HUTCHMED Wins NMPA Approval for ORPATHYS® in Gastric Cancer
Hong Kong, Shanghai & Florham Park, N.J., July 2, 2026 HUTCHMED has achieved a major regulatory milestone after the...
Daiichi Sankyo and AstraZeneca Secure EU Enhertu Approval
TOKYO, June 29, 2026 Daiichi Sankyo and AstraZeneca have announced that the European Commission (EC) has approved Enhertu® (trastuzumab...
Advertisements
AstraZeneca, Daiichi Sankyo Advance Datroway Toward EU Approval
CAMBRIDGE, UK & TOKYO, Japan, June 26, 2026 AstraZeneca and Daiichi Sankyo have moved one step closer to expanding...
AIM ImmunoTech Advances Ampligen Toward Potential Pivotal Development
OCALA, Fla., June 24, 2026 AIM ImmunoTech Inc. highlighted significant progress across its pancreatic cancer development program, positioning Ampligen®...
Alexion’s Ultomiris Gets FDA Priority Review for IgAN
BOSTON, US | June 15, 2026 Alexion, AstraZeneca Rare Disease announced that the U.S. Food and Drug Administration (FDA)...
AstraZeneca’s Truqap Becomes First Targeted Therapy Approved for PTEN-Deficient Prostate Cancer
CAMBRIDGE, United Kingdom, June 12, 2026 AstraZeneca has secured a major regulatory milestone with the U.S. Food and Drug...
AstraZeneca’s Ultomiris Shows Strong IgAN Phase III Results
GLASGOW, Scotland – June 6, 2026 AstraZeneca’s rare disease division, Alexion, has reported positive interim Phase III results for...
Advertisement
